Clinical Trial: A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137338) titled 'A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy' on July 25.

Brief Summary: This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Dilated Cardiomyopathy (DCM)

Intervention: GENETIC: RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogen...